This study will test the hypotheses that a single dose of oxyntomodulin (OXM) will be neutral or better than placebo in lowering ambient glucose levels during a graded glucose infusion (GGI) and that a single dose of OXM will lead to a statistically significant increase in the sum of the plasma βOHB + AcAc levels compared to placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
12
Single infusion of OXM 3.0 pmol/kg/min by IV
Single infusion of OXM 0.6 pmol/kg/min by IV
Single Placebo infusion of hemaccel-containing saline by IV
Ambient plasma glucose concentration during the GGI
Time frame: Last 160 minutes of OXM/placebo infusion
plasma βOHB + AcAc concentrations
Time frame: First 300 minutes of OXM/placebo infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.